Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia

Zaid H. Abdel Rahman1, Ricardo D. Parrondo1, Michael G. Heckman2, Mikolaj Wieczorek2, Kevin C. Miller3, Hassan Alkhateeb4, Lisa Z. Sproat5, Hemant Murthy1, William J. Hogan4, Mohamed A. Kharfan-Dabaja1, Jess F. Peterson6, Linda B. Baughn6, Nicole Hoppman6, Mark R. Litzow1, Rhett P. Ketterling6, Patricia T. Greipp6,*, James M. Foran1,*,

1Division of Hematology and Medical Oncology, Mayo Clinic, 2Division of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, FL, 3Department of Internal Medicine, Massachusetts General Hospital, Boston, MA, 4Division of Hematology, Mayo Clinic, Rochester, MN, 5Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, 6Department of Clinical Genomics, Mayo Clinic, Rochester, MN, USA

Summary

We report a comparative analysis of patients with therapy-related acute lymphoblastic leukaemia (tr-ALL) vs de novo ALL. We identified 331 patients with B-ALL; 69 (21%) were classified as tr-ALL. The most common prior malignancies were breast (23·2%) and plasma cell disorders (20·3%). Patients with tr-ALL were older (median 63·2 vs. 46·2 years, P < 0·001), more often female (66·7% vs. 43·5%, P < 0·001), and more likely to have hypodiploid cytogenetics (18·8% vs. 5·0%, P < 0·001). In multivariable analysis, patients with tr-ALL were less likely to achieve complete remission [odds ratio (OR) = 0·16, P < 0·001] and more likely to be minimal residual disease-positive (OR = 4·86, P = 0·01) but had similar OS after diagnosis and allo-haematopoietic cell transplantation.
Introduction
Therapy-related acute lymphoblastic leukaemia (tr-ALL) is a recently recognized, but poorly defined entity with an estimated incidence of 3–9% of ALL cases. Furthermore, most series combined tr-ALL with the so-called ALL with prior malignancy, a different entity that refers to patients with antecedent neoplasia but without exposure to cytotoxic therapy. Therapy-related ALL is associated with inferior survival outcomes compared to de novo ALL, partly because it has been shown to harbour high-risk genetic features, mainly hypodiploidy/near triploidy, KMT2A rearrangements, mono-somies 5, 7 and 17, complex karyotype as well as mutations usually seen in myeloid malignancies, such as DNMT3A, RUNX1 and ASXL1. The role of allogeneic haematopoietic cell transplantation (allo-HCT) is not well described; however, some reports suggested that it might abrogate the poor prognosis associated with tr-ALL despite being associated with increased non-relapse mortality.

Herein, we report a comparative analysis of patients with de novo ALL and tr-ALL to characterize the different clinical and cytogenetic features as well as outcomes between these two entities.

Materials and methods
After approval from the Mayo Clinic Institutional Review Board, we identified patients who received at least one cycle of therapy or allo-HCT for b-cell (B)-ALL between 1 January 2008 and 31 December 2019 at the Mayo Clinic Cancer Center.

We defined tr-ALL as ALL developing after prior exposure to cytotoxic chemotherapy or radiation for another malignancy. Patients were classified into the following cytogenetic groups: (i) Philadelphia chromosome positive (Ph+), t(9;22) (q34;q11.2)/BCR-ABL1 fusion; (ii) KMT2A rearrangement; (iii) t(1;19)(q21;p13.3)/TCF3-PBX1 fusion; (iv) hypodiploidy (30–39 chromosomes)/near triploidy (60–78 chromosomes); (v) hyperdiploidy (50–65 chromosomes); (vi) Philadelphia-like, as previously described; (vii) t(12;21)(p13;q22)/ETV6-RUNX1 fusion; (viii) normal karyotype and fluorescence in situ hybridization (FISH) panel; (ix) CDKN2A/p16 deletion; (x) 14q32 translocations/IGH rearrangements; (xi) complex karyotype, (≥5 chromosomal abnormalities in the absence of other class defining genetic alterations); and (xii) Others. Measurable residual disease (MRD) was measured using a flow cytometry assay with a sensitivity of 0.01% at the end of induction.

Statistical analysis
Comparisons of characteristics between tr-ALL patients and de novo ALL patients were made using a Wilcoxon rank sum test and Fisher’s exact test. Associations of tr-ALL with complete remission (CR) and MRD were examined using unadjusted and multivariable logistic regression models, where odds ratios (ORs) and 95% confidence intervals (CIs)
were estimated. For death after diagnosis and death after transplant, these were compared between tr-ALL patients and de novo ALL patients using unadjusted and multivariable Cox proportional hazards regression models; hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated. Kaplan-Meier survival estimates, and 95% CIs were also calculated, where censoring occurred on the date of last follow-up. For relapse and non-relapse mortality (NRM), cumulative incidences and 95% CIs were estimated while accounting for competing risks. Multivariable logistic and Cox regression models were adjusted for baseline variables that differed between tr-ALL and de novo ALL with a P-value < 0.05 and that had <5% missing data, allowing no more than one variable in the model for each ten events per recommended guidelines.9 In tr-ALL patients, the latency period was compared between cytogenetic groups using a Kruskal–Wallis rank sum test. P-values < 0.05 were considered statistically significant. Statistical analyses were performed using R Statistical Software (version 3.6.1; R Foundation for Statistical Computing, Vienna, Austria).

Results

Patient characteristics

We identified 331 patients with B-ALL, of whom 69 (21%) were classified as tr-ALL. A comparison of characteristics between tr-ALL and de novo ALL patients is shown in Table I. Prior malignancies and cytotoxic therapies are summarized in Table SI. The most common prior malignancies among tr-ALL patients were breast (23.2%), plasma cell disorder (20.3%), lymphoproliferative (17.4%), myeloid (14.5%) and genitourinary/gynaecologic (11.6%) malignancies. Chemotherapy was used in 59 (85.5%) patients, which included alkylating agents in 17 (24.6%) patients, topoisomerase II inhibitors in 4 (5.8%), and both in 19 (27.5%). Twenty-five (36.2%) patients were treated with radiation therapy and 15 (21.7%) patients had concurrent chemoradiation. Median latency period between exposure to prior cytotoxic therapy and development of tr-ALL was five years (range: 1–29 years) and was significantly longer for Philadelphia-positive compared to Philadelphia-negative B-ALL (median eight vs. four years, P = 0.02).

Compared with de novo ALL, patients with tr-ALL were older (median 63.2 vs. 46.2 years, P < 0.001), more often female [46 (66.7%) vs. 114 (43.5%), P < 0.001], less frequently of Hispanic ethnicity [2 (3.5%) vs. 34 (14.2%), P = 0.02] and had a lower median white blood cell (WBC) count on presentation (4.0 vs. 10.0 × 10^9/l, P = 0.003). Regarding cytogenetic subgroups, tr-ALL patients were more likely to have hypodiploidy/near triploidy [13 (18.8%) vs. 13 (5.0%), P < 0.001] and less likely to have Ph-like ALL [0 (0.0%) vs. 21 (8.0%), P = 0.01]. There was a similar incidence of Ph+ ALL in both groups [20 (29.0%) vs. 99 (37.8%), P = 0.21]. Patients with tr-ALL were less likely to receive paediatric-inspired regimens [2 (2.9%) vs. 49 (18.7%), P < 0.001] and less likely to proceed to allo-HCT [34 (49.3%) vs. 185 (70.6%), P = 0.001]. There were no differences between the two groups in ALL status at transplant (CR1 vs higher), donor type or graft type; however, patients with tr-ALL were less likely to have received a myeloablative conditioning regimen [15 (44.1%) vs 149 (81.0%), P < 0.001].
Outcomes

At the end of induction, 307 (92.7%) patients achieved a complete remission (CR) and 43 (42.6%, n = 101) patients were MRD-positive; a summary of outcomes can be found in Table II. In multivariable analysis adjusting for potential confounding variables, patients with tr-ALL had a significantly lower likelihood of achieving a CR (OR = 0.16, P < 0.001) and a higher likelihood of being MRD-positive when in remission (OR = 4.86, P = 0.01).

Median length of follow-up was 2.5 years (range: 7 days–18.0 years). Patients with tr-ALL had an inferior OS after diagnosis in unadjusted analysis, with a three-year OS of 40.2% compared to 63.8% for de novo ALL (HR =2.02, P < 0.001, Fig S1A); however, in multivariate analysis this difference weakened substantially and no longer approached statistical significance (HR = 1.17, P = 0.47). No statistically significant difference in OS after transplant between the two groups was noted in the subgroup that underwent allo-HCT in multivariable analysis (HR = 1.00, P > 0.99). Similarly, no significant differences between tr-ALL and de novo ALL groups were noted regarding relapse (HR = 1.24, P = 0.46) or NRM (HR = 1.04, P = 0.91) in multivariable analysis.

Discussion

We report a series of patients with therapy-related ALL using a strict definition of prior exposure to cytotoxic chemotherapy and/or radiation. In our cohort, patients with tr-ALL were older, less likely to achieve CR, more likely to be MRD-positive at the end of induction and had higher risk cytogenetics. Although patients with tr-ALL had an inferior OS in unadjusted analysis, this difference was greatly attenuated in multivariable analysis. We also noted that outcomes after allo-HCT (OS, NRM and relapse) were similar for both groups in multivariable analysis; this is likely the result of selection bias, where patients who are younger and more fit in the tr-ALL group received intensive up-front therapy and were able to proceed to allo-HCT.

Patients with tr-ALL were also more likely to be female than de novo ALL patients, likely a reflection of breast cancer as the most common primary malignancy. Another interesting demographic difference between the two groups was the lower likelihood of being of Hispanic ethnicity in the tr-ALL group, which coincides with the difference in Ph-like ALL incidence in both groups.

In our cohort, we noted a higher incidence of tr-ALL (21%) than what was previously reported in literature, which we attributed to referral patterns in the Mayo Clinic Cancer Center and enrichment of our cohort with patients with plasma cell disorders who are exposed to alkylating agents and immunomodulators along their treatment course. Three large phase 3 clinical trials have demonstrated a significant increased risk of secondary primary malignancies associated with lenalidomide maintenance following high-dose melphalan.10–12 The secondary primary malignancy risk ranged from 8% to 17% with 4–17% of those malignancies being haematologic malignancies without specifying the percentage of ALL cases. A recent study of 13 tr-ALL cases by Aldoss et al. analyzed paired samples of multiple myeloma and ALL using whole-exome sequencing and reported that tr-ALL arising in this setting is clonally unrelated to the multiple myeloma, supporting...
the notion that it represents a therapy-related leukaemia. Further research on tr-ALL in patients with antecedent multiple myeloma is warranted.

Patients with tr-ALL were more likely to have hypodiploid karyotype than patients with de novo ALL with deletions involving chromosome 17 as well as other monosomal chromosomes (e.g. chromosomes 5 and 7), this is consistent with previous reports and is likely a reflection of mitotic instability as a result of prior exposure to cytotoxic therapy. Another interesting observation is the occurrence of Ph+ ALL in the tr-ALL group with a similar incidence in the de novo ALL group. Ph+ ALL was also the most common genetic alteration in several series of tr-ALL, supporting the notion that BCR/ABL1 fusion can occur as a therapy-related abnormality after exposure to cytotoxic therapy.

Acknowledging the limitations of our study (e.g. retrospective design, relatively small sample size and corresponding possibility of type II error), our results support the recognition of tr-ALL as an important and unique clinical entity that deserves further investigation, as it is associated with distinctive and adverse cytogenetic and clinical features.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**Acknowledgements**

This publication is supported in part by a grant from the Conquer Cancer Foundation (CCF) of the American Society of Clinical Oncology (ASCO), and a Young Investigator Award (YIA) funded by the Florida Society of Clinical Oncology and awarded to Dr. Zaid H. Abdel Rahman. Some of the data in this publication were produced in the Mayo Clinic Cytogenetics Core Laboratory which is supported, in part, by a Mayo Clinic Comprehensive Cancer Center Grant, funded by National Cancer Institute (P30CA15083).

**Data availability statement**

Please contact the corresponding author at foran.james@mayo.edu.

**References**

1. Swaika A, Frank RD, Yang D, Finn LE, Jiang L, Advani P, et al. Second primary acute lymphoblastic leukemia in adults: a SEER analysis of incidence and outcomes. Cancer Med. 2018;7(2):499–507. [PubMed: 29282894]
2. Rosenberg AS, Brunson A, Paulus JK, Tuscano J, Wun T, Keegan THM, et al. Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance. Blood Cancer J. 2017;7(9):e605. [PubMed: 28885611]
3. Aldoss I, Dagis A, Palmer J, Forman S, Pullarkat V. Therapy-related ALL: cytogenetic features and hematopoietic cell transplantation outcome. Bone Marrow Transplant. 2015;50(5):746–8. [PubMed: 25730188]
4. Kelleher N, Gallardo D, González-Campos J, Hernández-Rivas JM, Montesinos P, Sarrá J, et al. Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy. Leukemia & Lymphoma. 2016;57(1):86–91. [PubMed: 25860236]
5. Aldoss I, Stiller T, Tsai N-C, Song JY, Cao T, Bandara NA, et al. Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute...
lymphoblastic leukemia, but outcomes are comparable in transplanted patients. Haematologica. 2018;103 (10):1662–8. 10.3324/haematol.2018.193599 [PubMed: 29903756]

6. Saygin C, Kishtagari A, Cassaday RD, Reizine N, Yurkiewicz I, Liedtke M, et al. Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Adv. 2019;3 (24):4228–37. [PubMed: 31869410]

7. Abdel Rahman ZH, Heckman MG, Miller K, Alkhateeb H, Patnaik MS, Sproat LZ, et al. Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALL. Transplantation and Cellular. Therapy. 2021;27(2):165.e1–165.e11.

8. Abdel-Rahman ZH, Heckman MG, Anagnostou T, White LJ, Kloft-Nelson SM, Knudson RA, et al. Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH-based algorithm distinguishes prognostic groups and outcomes. Blood Cancer Journal. 2021;11(9):156. [PubMed: 34548472]

9. Harrell F Regression Modeling Strategies. 1st ed, vol. XXIV. New York: Springer-Verlag; 2001. p. 572.

10. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782–91. [PubMed: 22571202]

11. Jones JR, Cairns DA, Gregory WM, Collett C, Pawlyn C, Sigsworth R, et al. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer J. 2016;6(12):e506. [PubMed: 27935580]

12. Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, et al. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017;4(9):e431–e42. [PubMed: 28826616]

13. Aldoss I, Capelletti M, Park J, Pistofidis RS, Pillai R, Stiller T, et al. Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma. Leukemia. 2019;33(1):266–70. [PubMed: 30026571]

14. Aldoss I, Douer D, Pullarkat V. Therapy-related acute lymphoblastic leukemia: Where do we stand with regards to its definition and characterization? Blood Rev. 2019;37:100584. [PubMed: 31235377]

15. Tang G, Zuo Z, Thomas DA, Lin P, Liu D, Hu Y, et al. Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related? Haematologica. 2012;97(6):919–25. 10.3324/haematol.2011.057752 [PubMed: 22207681]

16. Aldoss I, Stiller T, Song J, Al Malki M, Ali H, Salhotra A, et al. Philadelphia chromosome as a recurrent event among therapy-related acute leukemia. Am J Hematol. 2017;92(2):E18–E9. [PubMed: 27862221]
| Variable                        | n   | Median (minimum, maximum) or No. (%) of patients | P-value |
|--------------------------------|-----|-----------------------------------------------|---------|
|                                |     | Therapy-related ALL patients ($N = 69$)       | De novo ALL patients ($N = 262$) |         |
| Age at diagnosis (years)       | 331 | 63.2 (18.2, 83.5)                             | 46.2 (17.7, 88.8)               | <0.001  |
| Sex (male)                     | 331 | 23 (33.3%)                                    | 148 (56.5%)                     | <0.001  |
| Race                           | 320 |                                              |                                   |         |
| White                          | 59  | 59 (92.2%)                                    | 219 (85.5%)                     |         |
| Black                          | 2   | 2 (3.1%)                                      | 8 (3.1%)                        |         |
| Asian                          | 2   | 2 (3.1%)                                      | 8 (3.1%)                        |         |
| American Indian/Alaskan Native | 0   | 0 (0.0%)                                      | 8 (3.1%)                        |         |
| Other                          | 1   | 1 (1.6%)                                      | 13 (5.1%)                       |         |
| Ethnicity (Hispanic or Latino) | 297 | 2 (3.5%)                                      | 34 (14.2%)                      | 0.024   |
| WBC at diagnosis ($\times 10^9$/L) | 271 | 4.0 (0.5, 135.0)                             | 10.0 (0.0, 700.0)               | 0.003   |
| Hb at diagnosis (g/l)          | 251 | 98 (54, 148)                                  | 90 (0.0, 166)                   | 0.12    |
| Platelets at diagnosis (/μl)   | 255 | 64.0 (8.0, 313.0)                             | 45.5 (0.0, 519.0)               | 0.11    |
| Cyto genetic group             | 331 |                                              |                                   |         |
| t(9;22) BCR/ABL1               |     | 20 (29.0%)                                    | 99 (37.8%)                      | 0.21    |
| MLL (KMT2A) rearrangement      |     | 5 (7.2%)                                      | 11 (4.2%)                       | 0.34    |
| t(1;19) TCF3/PBX1              |     | 2 (2.9%)                                      | 5 (1.9%)                        | 0.64    |
| Hypodiploidy/near triploidy    |     | 13 (18.8%)                                    | 13 (5.0%)                       | <0.001  |
| Hyperdiploidy (HeH)            |     | 3 (4.3%)                                      | 14 (5.3%)                       | 1.00    |
| Ph-like                        |     | 0 (0.0%)                                      | 21 (8.0%)                       | 0.01    |
| Normal karyotype + FISH        |     | 6 (8.7%)                                      | 29 (11.1%)                      | 0.67    |
| Other                          |     | 14 (20.3%)                                    | 39 (14.9%)                      | 0.27    |
| CDKN2A (p16) deletion          |     | 2 (2.9%)                                      | 10 (3.8%)                       | 1.00    |
| IGH rearrangements             |     | 0 (0.0%)                                      | 6 (2.3%)                        | 0.35    |
| Complex                        |     | 4 (5.8%)                                      | 15 (5.7%)                       | 1.00    |
| Induction chemo                | 331 |                                              |                                   | <0.001  |
| HyperCVAD                      |     | 38 (55.1%)                                    | 169 (64.5%)                     |         |
| Paediatric regimens            |     | 2 (2.9%)                                      | 49 (18.7%)                      |         |
| Variable                             | \( n \) | Median (minimum, maximum) or No. (%) of patients | \( P \)-value |
|-------------------------------------|--------|-----------------------------------------------|--------------|
|                                     |        | Therapy-related ALL patients (\( N = 69 \)) | De novo ALL patients (\( N = 262 \)) |
|                                     |        | De novo ALL patients (\( N = 262 \)) |
| ECOG regimens                       | 9 (13.0%) | 23 (8.8%) | 0.36 |
| Others                              | 20 (29.0%) | 21 (8.0%) | 0.81 |
| CNS involvement                     | 331 | 9 (13.0%) | 23 (8.8%) | 0.002 |
| Allo-HCT                             | 331 | 34 (49.3%) | 185 (70.6%) | 1.00 |
| ALL status at allo-HCT              | 218 | 27 (79.4%) | 150 (81.5%) | 0.10 |
| CR1                                 | 2 (5.9%) | 11 (6.0%) | 0.001 |
| ≥CR2                                | 7 (20.6%) | 34 (18.5%) | 1.00 |
| Graft type                          | 218 | 2 (5.9%) | 11 (6.0%) | 0.10 |
| Bone marrow                         | 31 (91.2%) | 163 (88.6%) | 1.00 |
| Umbilical cord                      | 1 (2.9%) | 10 (5.4%) | 0.001 |
| Donor type                          | 218 | 15 (44.1%) | 60 (32.6%) | 1.00 |
| Matched related                     | 4 (11.8%) | 11 (6.0%) | 0.001 |
| Haploidentical                      | 15 (44.1%) | 113 (61.4%) | 1.00 |
| Matched unrelated                   | 15 (44.1%) | 113 (61.4%) | 1.00 |
| Conditioning regimen                | 218 | 15 (44.1%) | 149 (81.0%) | 0.001 |
| Myeloablative                       | 19 (55.9%) | 35 (19.0%) | 1.00 |

\( P \)-values result from a Wilcoxon rank sum test (continuous variables) or Fisher’s exact test (categorical variables). For cytogenetic group, and overall test of difference was performed followed by separate tests for each individual cytogenetic group. Statistically significant results are shown in bold. ALL, acute lymphoblastic leukemia; CNS, central nervous system; CR, complete response; ECOG, Eastern Cooperative Oncology Group; FISH, fluorescence in situ hybridization; HCT, hematopoietic cell transplantation; HyperCVAD, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; WBC, white blood cell count.
Table II.

Comparison of outcomes between therapy related and *de novo* ALL.

| Outcome/patient group | Number (%) of patients with the outcome | Cumulative incidence (%) at 3 years (95% CI) | Association measure | Unadjusted analysis | Multivariable analysis |
|-----------------------|----------------------------------------|---------------------------------------------|---------------------|---------------------|------------------------|
|                       |                                        |                                             |                     |                     |                        |
| MRD (positive)        |                                        |                                             | Odds ratio          |                     |                        |
| De novo ALL           | 28/80 (35.0)                           | N/A                                         | 1.00 (reference) N/A| 4.64 (1.69, 14.27)  | 0.004                  |
| Therapy-related ALL   | 15/21 (71.4)                           | N/A                                         | 1.00 (reference) N/A| 4.86 (1.47, 18.41)  | 0.013                  |
| Complete remission    |                                        |                                             |                     |                     |                        |
| De novo ALL           | 252/262 (96.2)                         | N/A                                         | 1.00 (reference) N/A| 0.16 (0.06, 0.37)   | <0.001                 |
| Therapy-related ALL   | 55/69 (79.7)                           | N/A                                         | 1.00 (reference) N/A| 0.16 (0.06, 0.43)   | <0.001                 |
| Survival after ALL diagnosis |                                      |                                             | Hazard ratio        |                     |                        |
| De novo ALL           | N/A                                    | 63.8 (58.1 – 70.2)                         | 1.00 (reference) N/A| 2.02 (1.39, 2.94)   | <0.001                 |
| Therapy-related ALL   | N/A                                    | 40.2 (28.5 – 56.6)                         | 1.00 (reference) N/A| 1.17 (0.77, 1.77)   | 0.47                   |
| Survival after allo-HCT |                                     |                                             | Hazard ratio        |                     |                        |
| De novo ALL           | N/A                                    | 61.9 (54.9 – 69.8)                         | 1.00 (reference) N/A| 1.00 (0.54, 1.85)   | 1.00                   |
| Therapy-related ALL   | N/A                                    | 48.6 (31.2 – 75.7)                         | 1.00 (reference) N/A| 1.24 (0.70, 2.22)   | 0.46                   |
| Relapse               |                                        |                                             | Hazard ratio        |                     |                        |
| De novo ALL           | N/A                                    | 27.4 (22.3 – 33.6)                         | 1.00 (reference) N/A| 1.00 (0.70, 2.22)   | 0.46                   |
| Therapy-related ALL   | N/A                                    | 31.1 (20.6 – 46.9)                         | 1.00 (reference) N/A| 1.34 (0.79, 2.28)   | 0.27                   |
| Non-relapse mortality |                                        |                                             | Hazard ratio        |                     |                        |
| De novo ALL           | N/A                                    | 17.9 (13.0 – 24.6)                         | 1.00 (reference) N/A| 1.00 (0.48, 2.29)   | 0.91                   |
| Therapy-related ALL   | N/A                                    | 35.5 (19.7 – 64.0)                         | 1.00 (reference) N/A| 1.80 (0.90, 3.63)   | 0.099                  |

Odds ratios, 95% CIs, and *P*-values result from logistic regression models. Hazard ratios, 95% CIs, and *P*-values result from Cox proportional hazards regression models. Multivariable models were adjusted for baseline variables that differed between *de novo* ALL and therapy-related ALL groups with a *P*-value < 0.05 and that had <5% missing data (excluding the Ph-like cytogenetic group, which could not be adjusted for due to the presence of a zero cell count), allowing no more than one variable in the model for each 10 ‘events’ per recommended guidelines, where an event is the minimum sample size of the two outcome categories in logistic regression, and the number of patients who experienced the outcome in Cox regression. These variables were age at diagnosis, sex, Ho-Tri (outcomes of MRD and non-relapse mortality), age at diagnosis (outcome of complete remission), and age at diagnosis, sex, Ho-Tri, and induction chemo (outcomes of survival after ALL diagnosis, survival after allo-HCT, and relapse). Statistically significant results are shown in bold. ALL, acute lymphoblastic leukemia; CI, confidence interval; HCT, haematopoietic cell transplantation; MRD, measurable residual disease.